Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab

The immunotherapy has revolutionized the world of oncology in the last decades with considerable advantages in terms of overall survival in cancer patients. The association of Pembrolizumab and Trastuzumab was recently proposed in clinical trials for the treatment of Trastuzumab-resistant advanced HER2-positive breast cancer. Although immunotherapies are frequently associated with a wide spectrum of immune-related adverse events, the cardiac toxicity has not been properly studied.

Source: International Journal of Cardiology - May 16, 2019 Category: Cardiology Authors: V. Quagliariello, M. Passariello, C. Coppola, D. Rea, A. Barbieri, M. Scherillo, M.G. Monti, R.V. Iaffaioli, M. De Laurentiis, P.A. Ascierto, G. Botti, C. De Lorenzo, N. Maurea Source Type: research